Articles tagged "Adverse effects"

2018 American Transplant Congress
Association between Everolimus Trough Levels, Onset of Related Adverse Events, and Treatment Discontinuation after Liver Transplantation: 24-Month Results from the H2304 Study
J. Fung,¹ F. Saliba,¹ H. Schlitt,¹ G. Junge,² K. McCague,³ D. Patel,³ M. Charlton.¹
¹H2304 Study Group, Chicago; ²Novartis Pharma AG, Basel, Switzerland; ³Novartis Pharmaceuticals Corporation, East Hanover.
Purpose: Evaluation of mammalian target of rapamycin inhibitor (mTORi)-related adverse events (AEs) and drug trough levels (C0) at onset may aid their management in liver…
2018 American Transplant Congress
Preventing Recurrence of Incisional Hernia after Liver Transplantation
J. Butler, D. O'Brien, J. Kays, C. Kubal, B. Ekser, J. Fridell, R. Mangus, J. Powelson.
Transplant Surgery, Indiana University, Indianapolis, IN.
Background: Incisional hernia is a well-known complication of orthotopic liver transplantation (OLT). Although factors that affect incidence of hernia after OLT have been described, recurrence…
2018 American Transplant Congress
Post-Hoc Analysis of Everolimus Trough Levels around the Onset of Related Adverse Events and Treatment Discontinuation in De Novo Kidney Transplant Recipients from the US92 Study
F. Shihab,¹ Y. Qazi,¹ V. Peddi,¹ D. Shaffer,¹ K. McCague,² D. Patel,² S. Mulgaonkar.¹
¹US92 Study Group, Salt Lake City; ²Novartis Pharmaceutical Corporation, East Hanover.
Purpose: Around 30%-50% of kidney transplant recipients (KTR) on sirolimus discontinue treatment due to drug-related adverse events (AE) and ~23% on everolimus (EVR) discontinue treatment…
2018 American Transplant Congress
Closing Pandora's Box: An Evidence Based Approach to Opioid-Tolerant Patients Following Transplantation. The Case for IV Methadone
A. Aljassem, L. Hall, S. Cohn, D. Bedi, M. Alsibae, K. Putchakayala, S. Tasleem, D. Samarapungavan, C. Carpenter, A. Koffron.
Department of Surgery, Beaumont Health, Royal Oak, MI.
The purpose of this study is to explore the use of parenteral methadone in opioid-tolerant patients who are status-post transplantation. As an alternative to traditional…
2018 American Transplant Congress
Renal-Sparing Protocol May Be Harmful If Performed Early Post-Heart Transplant
J. Patel, M. Johl, E. Kransdorf, M. Kittleson, S. Dimbil, R. Levine, D. Chang, L. Czer, J. Kobashigawa.
Cedars Sinai Medical Center, Los Angeles, CA.
Purpose: Calcineurin inhibitors (CNIs) are associated with nephrotoxicity. Renal sparing protocol (RSP) with CNI free regimen using mycophenolate and a proliferation signal inhibitor may improve…
2018 American Transplant Congress
Patient Experience after Kidney Transplant: Factors That Lessen the Burden of Treatment after Kidney Transplant
E. Lorenz,¹ J. Egginton,¹ M. Stegall,¹ R. Heilman,² S. Nair,² M. Mai,³ D. Eton.¹
¹Mayo Clinic, Rochester; ²Mayo Clinic, Scottsdale; ³Mayo Clinic, Jacksonville.
Background: Patients face a daunting regimen of medications, health monitoring and medical appointments following kidney transplant. This workload of healthcare and its impact on patient…
2018 American Transplant Congress
Belatacept and Tacrolimus Corticosteroid-Free Regimens Lead to Elevated Mycophenolic Acid Exposure at 1 and 3 Months after Kidney Transplantation
A. Dao, S. Tremblay, A. Shields, A. Loethen, B. Abu Jawdeh, T. Diwan, A. Govil, E. Woodle, R. Alloway.
UCincinnati, Cincinnati.
Mycophenolate mofetil (MMF) is generally administered as a fixed dose. Studies have shown a relationship between MPA exposure (MPAAUC) but no data evaluates this relationship…
2018 American Transplant Congress
Efficacy and Safety of a Single-Dose Rituximab for Prevention of Focal Segmental Glomerulosclerosis Recurrence after Kidney Transplant
Y. Lu,¹ J. Lyons,² S. Tischer,² K. Woodside,³ J. Park.²
¹Transplant Nephrology, University of Michigan, Ann Arbor, MI; ²Transplant Pharmacy, University of Michigan, Ann Arbor, MI; ³Transplant Surgery, University of Michigan, Ann Arbor, MI.
Background: For patients with end stage renal disease (ESRD) due to primary focal segmental glomerulosclerosis (FSGS), there is a significantly increased risk for disease recurrence…
2018 American Transplant Congress
The Infusion with a Difference: Patient Experiences with Belatacept
H. Murad, D. Malhotra, E. Cohen, W. Asch.
Yale University, New Haven, CT.
Introduction: The results of the BENEFIT trial led to the FDA approval of the novel anti-rejection agent belatacept (bela) in 2011. In addition to its…
2018 American Transplant Congress
Conversion from Twice Daily Immediate Release Tacrolimus to Once Daily Extended Release Tacrolimus (LCP-Tacro) in High Risk Kidney Transplant Recipients
M. Benincasa,¹ V. Colomy,¹ N. Sifontis,¹ S. Rao,² K. Lau,³ S. Karhadkar,³ A. Di Carlo,³ A. Diamond.⁴
¹Pharmacy Practice, Temple School of Pharmacy, Philadelphia, PA; ²Medicine, Temple School of Medicine, Philadelphia, PA; ³Surgery, Temple School of Medicine, Philadelphia, PA; ⁴Pharmacy, Temple University Hospital, Philadelphia, PA.
Extended release once daily tacrolimus (LCP-Tacro) has demonstrated non inferiority to immediate release twice daily tacrolimus (IR-Tac) in kidney transplantation. These data are limited by…